• Home
  • Our Capabilities
  • Our People
    • Naomi Pearce
    • Jacinta Flattery O’Brien PhD
    • Jennifer Enmon PhD JD
    • Grant Shoebridge PhD
    • Kadri Elcoat
    • Kate Legge
    • Lesley White
    • Alex May
    • Christopher Coates
    • Jessica Chadbourne PhD
    • Joanne Grant
    • Emily Bristow
    • Brittany Deleon
    • Erni Othman
    • Amber Cross
  • News
    • Pearce IP Blog
    • BioBlast™
  • Blog
  • BioBlast™
  • Contact Us

Celltrion receives approval for biosimilar infliximab from Health Canada

by Bioblast Editor | Feb 1, 2021 | Biosimilars updates

Celltrion announces it has received a notice of compliance from Health Canada for Remsima® SC (subcutaneous infliximab). Remsima® has been approved for the treatment of rheumatoid arthritis.

New study shows long-term biosimilarity of Truxima® to Rituxan®

by Bioblast Editor | Dec 11, 2020 | Biosimilars updates

A new long-term efficacy and safety study demonstrated the biosimilarity of Celltrion’s CT-P10/Truxima® (infliximab) to Rituxan® at 27 months in patients with low-tumor burden follicular lymphoma.

Celltrion’s Remsima® in auto-injection pen approved by TGA

by Bioblast Editor | Nov 12, 2020 | Biosimilars updates

The TGA approves Celltrion’s subcutaneous “biobetter” infliximab product Remsima® in auto-injection pen and PFS presentations. This is the first subcut infliximab product to be approved in Australia.

Results from post-marketing studies of Renflexis® released by Samsung Bioepis

by Bioblast Editor | Oct 26, 2020 | Biosimilars updates

Samsung Bioepis announces results from two post-marketing studies of Renflexis® (biosimilar infliximab) in Veteran Affairs patients with IBD. The first study evaluated the safety of switching from reference infliximab to Renflexis®, finding that patients who were on...

Celltrion presents interim results at the UEG Week Virtual 2020

by Bioblast Editor | Oct 10, 2020 | Biosimilars updates

Celltrion presents positive interim results from Ph I trials of CT-P13 of subcutaneous Remsima® (biosimilar infliximab) in IBD at the UEG Week Virtual 2020. The results indicated that subcutaneous infliximab may be associated with better clinical outcomes compared to...
Page 1 of 1212345...10...»Last »

SUBSCRIBE TO PEARCE IP

Sign up to our latest news

Receive our Pearce IP Blog and weekly BioBlast™ via email.

SUBSCRIBE
  • Our People
  • Our Capabilities
  • News
  • Blog
  • BioBlast™
  • Contact Us
  • Follow

Copyright © 2021 Pearce IP. All Rights Reserved.

Contact Us

Email: info@pearceIP.law
Tel: +61 (0) 2 9023 9988

For any general inquiries, please fill in the following contact form:

 





    Subscribe to our BioBlast™

    Fill in the form below to recieve our BioBlast™ Updates, Pearce IP Blog and other relevant industry updates.

     



      What emails do you want to receive?